1. Home
  2. /
  3. Venture Capital
  4. /
  5. MRM Health Reports Positive...

News / Venture Capital

MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis

19 September 2023
MRM Health NV, a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics, today reports positive topline results from its Phase 2a clinical trial with MH002 in mild-to-moderate Ulcerative Colitis (UC).

Download

Press Release
Download

Related News

arrow-up-right
Deepull-logo
arrow-up-right